March 7,Novo NordiskHosted the Capital Markets Day (CMD) event, where presentations by senior management of Novo Nordisk covered corporate strategy and goals with sustainability (ESG), research and early development, product offerings in diabetes, obesity, and rare diseases, as well as R&D pipeline and performance. Additionally, Novo Nordisk’s approaches and financial status in cardiovascular and emerging therapeutic areas were introduced.
At the same time, Novo Nordisk also announced its new weight-loss candidate drug.Amycretin(A novel GLP-1 andLong-acting co-agonist of amylin) and Monlunabant (Oral Small Molecule CB1R Inverse Agonist) Positive Phase I Data.Novo Nordisk TargetsAmycretinTwo formulations, oral and subcutaneous injection, have been developed. The data disclosed this time are for the oral formulation, and the Phase I data for the subcutaneous formulation are expected to be obtained in 2025.The study results showed that taking Amycretin once daily orally led to a 13.1% weight loss after 12 weeks.Amycretin has good safety and tolerability.The Phase I study results of Monlunabant showed that on Day 28, MonluThe nabant group experienced an average weight loss of 3.5 kg (3.3%), while the placebo group gained 0.6 kg (0.5%). Monlunabant demonstrated good safety and tolerability, with the most common side effects being gastrointestinal reactions.Positive Results of Two Early-Stage Weight Loss Candidate Drugs Also Boost Novo Nordisk's Stock PriceSurged nearly 9%, market value hit a record high, surpassing $600 billion.Copyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.↑Long press to identify QR code / ScanRegistration is now open.↑
